Compare Abeona Therapeutics Inc (ABEO) vs Citigroup Inc. (C) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Citigroup Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Citigroup Inc. trades at $137.4 (market cap $240.09B). The key difference: Citigroup Inc. is far larger — about 643.1× Abeona Therapeutics Inc's market cap, and Citigroup Inc. pays a 1.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | C | |
|---|---|---|
Market Cap | $373.32M | $240.09B |
Sector | Health | Financials |
52-Week High | $7.23 | $145.67 |
52-Week Low | $4.17 | $85.57 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Citigroup (C) trades at $140.75, up 0.59% today, with a bullish technical outlook and strong analyst support. Recent Q1 2026 earnings beat expectations, and the company expanded its services by joining LPMCL. Revenue and net income have grown steadily, with a P/E of 17.78 and a consensus price target of $151.36. The stock is near its 52-week high, reflecting positive momentum.
The outlook is positive, driven by earnings growth and strategic expansions, but risks include volatile cash flows and high debt levels. Wall Street sentiment is bullish, with 59% of analysts rating it a buy. Investors should weigh the strong fundamentals against macroeconomic and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
